When reporters in November were scrambling to interpret the results of a Pfizer clinical trial showing its cholesterol drug outperformed a Bristol-Myers medicine, Bristol brought out Dr. Christopher Cannon to caution about drawing hasty conclusions.
When reporters in November were scrambling to interpret the results of a Pfizer clinical trial showing its cholesterol drug outperformed a Bristol-Myers medicine, Bristol brought out Dr. Christopher Cannon to caution about drawing hasty conclusions.